Physician profile
Rosa J Cuenca
NPI 1134124654
$1,973.92
in general payments reported to CMS, 2019-2025
20 companies · $682 in 2025
The $682 reported for 2025 was more than what 78% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $20.81 · 2021: $56.42 · 2022: $120 · 2023: $435 · 2024: $507 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,623.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $409.01 | 2024-2025 | |
| Abbvie INC. | $248.93 | 2023 | Creon, Linzess |
| Regeneron Healthcare Solutions, INC. | $246.66 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $174.68 | 2019-2025 | Sucraid, Sucraid |
| Alcresta Therapeutics, INC. | $157.87 | 2024-2025 | Relizorb |
| Nestle Healthcare Nutrition INC. | $115.41 | 2020-2023 | |
| Regeneron Pharmaceuticals, INC. | $97.39 | 2024 | Dupixent |
| Ironwood Pharmaceuticals, INC | $77.08 | 2023-2024 | Linzess |
| Pharming Healthcare, INC. | $76.81 | 2024 | Ruconest |
| Neuraxis, INC. | $66.99 | 2024 | |
| Coloplast Corp | $57.52 | 2019-2023 | Peristeen |
| Aimmune Therapeutics, INC. | $48.35 | 2024 | |
| Alexion Pharmaceuticals, INC. | $36.23 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.07 | 2025 | Gattex, Eohilia |
| Phadia US INC. | $33.86 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $21.90 | 2023 | Pancreaze |
| Rhythm Pharmaceuticals, INC. | $21.78 | 2023 | Imcivree |
| Travere Therapeutics, INC. | $19.98 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $14.69 | 2024 | Iqirvo |
| Allergan, INC. | $13.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosa Cuenca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.